Open AccessThe Association of Coagulation Indicators and Coagulant Agents With 30-Day Mortality of Critical Diabetics
Author(s) -
Yingxin Huang,
Zhihua Zhong,
Fanna Liu
Publication year - 2021
Publication title -
clinical and applied thrombosis/hemostasis
Language(s) - English
Resource type - Journals
eISSN - 1938-2723
pISSN - 1076-0296
DOI - 10.1177/10760296211026385
Subject(s) - medicine , diabetes mellitus , proportional hazards model , hazard ratio , receiver operating characteristic , risk of mortality , survival analysis , retrospective cohort study , confidence interval , endocrinology
Diabetes, regarded as a global health concerned disease, was focused by the World Health Organization (WHO). Patients with diabetes may have a hypercoagulable and hypo-fibrinolysis state. There is lots of research about cardiovascular effects on diabetes patients, but less about the coagulation system. This study is designed to investigate the relationship between coagulation indicators and 30-day mortality of critical diabetes patients. In this retrospective, single-center study, we included adult patients diagnosed with diabetes. Data, including demographic, complication, laboratory tests, scoring system, and anticoagulant treatment, were extracted from Medical Information Mart for Intensive Care (MIMIC-III). The receiver operating characteristic (ROC) curve and Kaplan-Meier curve were applied to predict the association of mortality and coagulation indicators. Cox hazard regression model and subgroup analysis were used to analyze the risk factors associated with 30-day mortality. A total of 4026 patients with diabetes mellitus were included in our study, of whom 3312 survived after admitted to the hospital and 714 died. Cox hazard regression showed anticoagulant therapy might decrease the risk of 30-day mortality after adjusted. In age 70, lightly increased PTT may reduce the risk of mortality, but PT >16.3 s, a high level of hypo-coagulation state, increase risk of mortality (HR, 95%CI, 0.756 (0.574, 0.996), 1.756 (1.129, 2.729)). Critical diabetes patients may benefit from anticoagulant agents. The abnormal coagulant function is related to the risk of 30-day mortality.